|
U.S. Centers for Disease Control and Prevention
• International News
Bristol-Myers Squibb, Gilead to Sell Atripla in Canada
October 2, 2006 Expanding on their US joint venture launched in December 2004, drug makers Bristol-Myers Squibb Co. and Gilead Sciences have agreed to market their once-daily HIV treatment Atripla in Canada, pending approval by Health Canada. The companies will jointly file paperwork with Canadian regulators, and they will contribute funding and staff for the additional sales. Atripla -- which combines fixed doses of BMS' Sustiva and Gilead's Viread and Emtriva -- received US Food and Drug Administration approval in July. Back to other news for October 2, 2006 Associated Press 09.29.2006 This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. |
|
